C07C223/04

Highly enantioselective access to cyclic beta-amino acids

Disclosed herein is a method of forming a compound of formula I: ##STR00001##
wherein the substituents are defined in the specification. In particular, the compounds of formula I can be converted to amino acids bearing quaternary stereocenters with exceptional optical purities.

Highly enantioselective access to cyclic beta-amino acids

Disclosed herein is a method of forming a compound of formula I: ##STR00001##
wherein the substituents are defined in the specification. In particular, the compounds of formula I can be converted to amino acids bearing quaternary stereocenters with exceptional optical purities.

HIGHLY ENANTIOSELECTIVE ACCESS TO CYCLIC BETA-AMINO ACIDS
20210171436 · 2021-06-10 ·

Disclosed herein is a method of forming a compound of formula I:

##STR00001##

wherein the substituents are defined in the specification. In particular, the compounds of formula I can be converted to amino acids bearing quaternary stereocenters with exceptional optical purities.

HIGHLY ENANTIOSELECTIVE ACCESS TO CYCLIC BETA-AMINO ACIDS
20210171436 · 2021-06-10 ·

Disclosed herein is a method of forming a compound of formula I:

##STR00001##

wherein the substituents are defined in the specification. In particular, the compounds of formula I can be converted to amino acids bearing quaternary stereocenters with exceptional optical purities.

Ascochlorin derivative and use thereof as AMPK activator
10968186 · 2021-04-06 · ·

An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.

Ascochlorin derivative and use thereof as AMPK activator
10968186 · 2021-04-06 · ·

An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.

ASCOCHLORIN DERIVATIVE AND USE THEREOF AS AMPK ACTIVATOR
20200270220 · 2020-08-27 ·

An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.

Method of whitening skin using tranexamic acid-peptide having skin whitening activity

A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.

METHOD OF WHITENING SKIN USING TRANEXAMIC ACID-PEPTIDE HAVING SKIN WHITENING ACTIVITY

A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.

Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.